Company: INDP
Filing Date: 2025-03-13
Form Type: 10-K
Source: 0001493152-25-010136
Chunk: 73

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-03-13
Form: 10-K
Item: Item 1
Chunk 73
---
application process. In many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the
applicable rules. However, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application,
resulting in partial or complete loss of patent rights in the relevant jurisdiction. If this occurs with respect to our in-licensed patents
or patent applications we may file in the future, our competitors might be able to use our technologies, which would have a material
adverse effect on our business, financial condition and results of operations.

The
patent positions of products are often complex and uncertain. The breadth of claims allowed in patents in the U.S. and many jurisdictions
outside of the U.S. may not be consistent. Changes in either the patent laws or interpretations of patent laws in the U.S. and other
countries may diminish the value of our licensed or owned intellectual property or create uncertainty. In addition, publication of information
related to our current product candidates and potential products may prevent us from obtaining or enforcing patents relating to these
product candidates and potential products, including without limitation composition-of-matter patents, which are generally believed to
offer the strongest patent protection.

Patents
that we may own now or may own or license in the future do not necessarily ensure the protection of our licensed or owned intellectual
property for a number of reasons, including, without limitation, the following:

    ●
    the
    patents may not be broad or strong enough to prevent competition from other products that are identical or similar to our product
    candidates;

    ●
    there
    can be no assurance that the term of a patent can be extended under the provisions of patent term extensions afforded by U.S. law
    or similar provisions in foreign countries, where available;

    ●
    the
    issued patents and patents that we may own now or may obtain or license in the future may not prevent generic or biosimilar entry
    into the market for our product candidates;

    ●
    we,
    or third parties from whom we in-license or may license patents, may be required to disclaim part of the term of one or more patents;

    ●
    there
    may be prior art of which we are not aware that may affect the validity or enforceability of a patent claim;

    ●
    there
    may be prior art of which we are aware, which we do not believe affects the validity or enforceability of